AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLC

Author:

Wu Mingsheng1,Xiong Ran1,Wang Gaoxiang1,Chen Xiao1,Wu Xianning1,Sun Xiaohui1,Xu Guangwen1,Xu Meiqing1,Xie Mingran1

Affiliation:

1. The First Affiliated Hospital of USTC, University of Science and Technology of China

Abstract

Abstract Targeted therapy for lung cancer research has advanced quickly in recent years, particularly EGFR-TKIs in the grouping of EGFR-mutant lung cancer, however clinical treatment has encountered difficulties with acquired drug resistance. Due to their great specificity, few adverse reactions, and prolonged tumor control duration, immune checkpoint inhibitors PD-1 and PD-L1 antibodies have emerged as a new therapy approach for NSCLC with the advancement of tumor biology. AXL, a gene that codes for receptor tyrosine kinases, has been linked to the growth, treatment resistance, and immunological imbalance of cancer cells. Its protein has been found to be abnormally expressed in NSCLC cancer tissues. Our study shows a positive regulatory link between AXL and PD-L1 expression, and AXL can upregulate PD-L1 to facilitate the development of acquired drug resistance in EGFR-mutant lung cancer treated with gefitinib. We offer additional understandings for AXL to overcome the gefitinib resistance mechanism in NSCLC, while also providing ideas for addressing targeted therapy resistance.

Publisher

Research Square Platform LLC

Reference32 articles.

1. GREENHALGH J, BOLAND A, BATES V et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer [J].Cochrane Database Syst Rev, 2021,3.

2. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [J];SORIA JC;N Engl J Med,2018

3. SIM E H, YANG I A, WOOD-BAKER R et al. Gefitinib for advanced non-small cell lung cancer [J].Cochrane Database Syst Rev, 2018,1.

4. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer [J];TAN C S, CHO B C, SOO RA;Lung Cancer,2016

5. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer [J];ZHANG K;J Cancer Res Ther,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3